

Provider Frequently Asked Questions: Long-acting Injectable Buprenorphine Funding Program FY26-27

Background

The long-acting injectable (LAI) buprenorphine funding program is for small providers treating the uninsured. Small providers are defined as a clinic with 5 or fewer licensed prescribers that prescribe Sublocade or Brixadi, not owned or operated by a hospital or carceral facility.

Through Engrossed Substitute Senate Bill 5167, Section 214(58), the Legislature appropriated \$2,000,000 of the opioid abatement settlement account to the Health Care Authority (HCA) to increase access to long-acting injectable buprenorphine products during fiscal years 2026 and 2027.

HCA must use these funds to:

- 1) Provide LAI buprenorphine products to small providers that are not financially affiliated with a hospital nor will any provider administer the medications received through this program to a patient in a carceral facility; and
- 2) Cover the cost and administration of the drug for uninsured individuals that do not qualify for other state or federal health insurance programs.

Learn more by reading [Senate Bill 5167, Section 214\(58\), page 210](#).

What are the program objectives?

- 1) Allow small providers to have LAI buprenorphine stocked in the clinic when an uninsured patient with opioid use disorder comes in.

How will the program work?

- 1) Provider fills out Sections 2 and 4 of the [Participating Provider Agreement](#). **Do not sign the Agreement.** Send Agreement to pdp@hca.wa.gov.
- 2) HCA determines if provider is eligible. Once accepted into the program, HCA will send the Agreement for signature.
- 3) Provider will be sent the relevant documents to set up a MMCAP Infuse ID, and distributor account.
- 4) Provider's REMS certification will be validated.
- 5) Provider will receive access to distributor website with option to order Sublocade and Brixadi.
- 6) The amount of funds the provider can utilize will be determined by HCA.
- 7) HCA will approve all orders.
- 8) Medication will be shipped to clinic; HCA will be billed.

- 9) Provider submits monthly reconciliation report to HCA.
- 10) HCA pays provider administration fee for uninsured clients.
- 11) Repeat steps 6-10 until funds are exhausted or deadline is reached.

Am I eligible?

For HCA to determine eligibility under this program, the provider must meet the following requirements:

- 1) Clinic is not owned by a hospital.
- 2) Clinic is not owned by a carceral facility, and no medication received through this program will be administered to a patient in a carceral facility.
- 3) Clinic has 5 or fewer licensed prescribers that prescribe Sublocade or Brixadi for opioid use disorder. If clinic has more than 5 prescribers, please submit a letter with your application justifying why the clinic should be considered a small provider, including location and population served.
- 4) Clinic is Risk Evaluation and Mitigation Strategy (REMS) certified for Sublocade or Brixadi or both.
- 5) Medication will be stored according to REMS.
- 6) Clinic treats uninsured patients.

How will I continue to stock LAI buprenorphine?

HCA contracted with MMCAP Infuse, a group purchasing organization for government facilities, to get their discounted rate on LAI buprenorphine products. If the clinic is a non-profit, they are eligible to open their own MMCAP Infuse account. Non-profit clinics will then be able to continue bulk purchasing LAI buprenorphine products when this program ends.

When will the program end?

These funds are available through June 30, 2027. This program ends on June 30, 2027, or when funding is exhausted, whichever occurs first.

How do I apply?

- 1) Fill out Sections 2 and 4 of the [Participating Provider Agreement](#). **Do not sign the Agreement.** Once accepted into the program, HCA will send the Agreement for signature.
- 2) Send to pdp@hca.wa.gov.
- 3) **Deadline for submissions is COB Oct 31, 2025.**